Dacomitinib Tablet
Brand names: Vizimpro
Category: Oncology
FDA status: To Be Discontinued · Last FDA update: Jun 8, 2026 · First posted: Jun 8, 2026 · 1 manufacturers, 3 listed presentations
As of Jun 8, 2026, the FDA lists Dacomitinib Tablet as being discontinued. Of 3 manufacturer presentations, 3 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Vizimpro, Tablet, 15 mg (NDC 0069-0197-30) NDC 0069-0197-30 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug |
| Vizimpro, Tablet, 30 mg (NDC 0069-1198-30) NDC 0069-1198-30 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug |
| Vizimpro, Tablet, 45 mg (NDC 0069-2299-30) NDC 0069-2299-30 |
Pfizer Inc. | Not specified | Discontinuation of the manufacture of the drug |
Related medications in shortage
Other Oncology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Dacomitinib Tablet (FDA data as of Jun 8, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Dacomitinib Tablet. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/dacomitinib-tablet.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).